Arlesheim, Switzerland
Drossapharm, a Swiss pharmaceutical company founded in 1976, has positioned itself as an independent leader in the highly competitive pharmaceutical sector. With its headquarters in Switzerland, it has a focused strategy on developing and manufacturing innovative medicinal products, mainly for rheumatic diseases, injuries, vascular complaints, dermatologies, and gynecologic disorders.
The company differentiates itself by specializing in specific indication areas and active principles, offering a robust portfolio of high-quality, prescription-required drugs. The customer base encompasses physicians, pharmacies, and hospitals, emphasizing its integral role in the health sector ecosystem. Despite its long-standing presence in the market, Drossapharm has not reported recent investments, signaling a potential opportunity for venture capitalists looking to invest in a stable, mature company with a well-defined niche and a strong Swiss heritage.
